Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
Glaukos
Glaukos beats The Street in Q1 results
Glaukos (NYSE:GKOS) posted first-quarter results that beat the overall consensus on Wall Street. The San Clemente, Calif.-based ophthalmic medical technology company yesterday reported losses of -$16.469 million, or -36¢ per share, on sales of $67.968 million for the three months ended March 31, for a sales growth of 22.83% compared with Q1 2020. Adjusted to […]
Glaukos inks licensing deal with Intratus for Eyelid drug delivery platform
Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform. San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed. Get the full […]
The 18 most innovative medical devices of 2020
The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, we are honored […]
Glaukos announces $200m offering
Glaukos (NYSE:GKOS) announced today that it intends to offer convertible senior notes worth $200 million in a private offering. San Clemente, Calif.-based Glaukos is offering the notes, due in 2027, only to qualified institutional buyers with a 13-day option for initial purchasers to purchase up to an additional $30 million in notes, according to a news […]
Glaukos down despite Street-beating Q4
Glaukos (NYSE:GKOS) shares plummeted today despite fourth-quarter results that beat the consensus forecast. GKOS shares dropped down -27.4% at $44.60 per share in early-morning trading today. The San Clemente, Calif.–based ophthalmic medical technology and pharmaceutical company posted profits of $36.6 million, or 84¢ per share, on sales of $65.8 million for the three months ended Dec. […]
Procept Biorobotics taps industry veteran as new CEO
Procept BioRobotics recently announced that Reza Zadno, former CEO of ophthalmology tech company Avedro, has taken over the corner office at Procept. Zadno has more than three decades of leadership in the medical device industry, with a track record of successfully leading young companies to acquisitions. The latest was Avedro, which Glaukos (NYSE:GKOS) acquired for an […]
Glaukos completes Avedro buy
Glaukos (NYSE:GKOS) today said it completed its acquisition of Glaukos for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. Get the full story on our sister site, Drug Delivery Business.
Glaukos slides on Q3 profit drop
Glaukos (NYSE:GKOS) shares dropped today on third-quarter earnings that topped the consensus forecast despite sliding profits. The San Clemente, Calif.-based ophthalmic medical technology and pharmaceutical company posted losses of -$13.5 million, or -37¢ per share, on sales of $58.5 million for the three months ended Sept. 30, for a large bottom-line slide on sales growth of […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
On mixed Q2 results, Glaukos announces Avedro buy
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]